QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

被引：0
|
作者：
P Ghatalia
Y Je
M D Kaymakcalan
G Sonpavde
T K Choueiri
机构：
[1] University of Alabama at Birmingham (UAB),Department of Internal Medicine
[2] Kyung Hee University,Department of Food and Nutrition
[3] Dana Farber Cancer Institute and Harvard Medical School,Department of Internal Medicine
[4] Section of Medical Oncology,undefined
[5] UAB Medical Center,undefined
来源：
British Journal of Cancer | 2015年 / 112卷
关键词：
vascular endothelial growth factor receptor; tyrosine kinase inhibitors; approved; QTc interval prolongation; meta-analysis; cardiac toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：296 / 305
页数：9
相关论文
共 50 条
  • [1] QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
    Ghatalia, P.
    Je, Y.
    Kaymakcalan, M. D.
    Sonpavde, G.
    Choueiri, T. K.
    BRITISH JOURNAL OF CANCER, 2015, 112 (02) : 296 - 305
  • [2] Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors
    Roy, Bhaskar
    Das, Avash
    Ashish, Kumar
    Bandyopadhyay, Dhrubajyoti
    Maiti, Abhishek
    Chakraborty, Sandipan
    Stone, Martha E.
    Philpotts, Lisa Liang
    Nowak, Richard J.
    Patwa, Huned S.
    NEUROLOGY, 2019, 93 (02) : E143 - E148
  • [3] Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors
    Ghatalia, Pooja
    Morgan, Charity J.
    Choueiri, Toni K.
    Rocha, Pedro
    Naik, Gurudatta
    Sonpavde, Guru
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (01) : 136 - 145
  • [4] Vascular endothelial growth factor tyrosine kinase inhibitors
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (06) : 921 - 924
  • [5] Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia, Pooja
    Morgan, Charity
    Choueiri, Toni K.
    Rocha, Pedro
    Naik, Gurudatta
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors
    Langer, CJ
    Natale, RB
    SEMINARS IN ONCOLOGY, 2005, 32 (06) : S23 - S29
  • [7] Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
    Kloth, J. S. L.
    Pagani, A.
    Verboom, M. C.
    Malovini, A.
    Napolitano, C.
    Kruit, W. H. J.
    Sleijfer, S.
    Steeghs, N.
    Zambelli, A.
    Mathijssen, R. H. J.
    BRITISH JOURNAL OF CANCER, 2015, 112 (06) : 1011 - 1016
  • [8] Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
    J S L Kloth
    A Pagani
    M C Verboom
    A Malovini
    C Napolitano
    W H J Kruit
    S Sleijfer
    N Steeghs
    A Zambelli
    R H J Mathijssen
    British Journal of Cancer, 2015, 112 : 1011 - 1016
  • [9] Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
    Ghatalia, Pooja
    Morgan, Charity J.
    Je, Youjin
    Nguyen, Paul L.
    Quoc-Dien Trinh
    Choueiri, Toni K.
    Sonpavde, Guru
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (02) : 228 - 237
  • [10] Risk of QTC interval prolongation among cancer patients treated with tyrosine kinase inhibitors
    Abu Rmilah, A.
    Lin, G.
    Hermann, J.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3586 - 3586
12345